Correlation of apelin with microalbuminuria in type 2 diabetic patients
Curr Issues Pharm Med Sci., Vol. 36, No. 1, 45-47
Johnbasha Shaik1*
, Kanumuru Balu Mahendran2, Durairajan Sheela3,
Vudaga Krishna Murthy4, Tadi Santhi4
1 Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha Deemed University, Thandalam, India
2 Department of Biochemistry, Siddhartha Medical College, India
3 Department of Pharmacology, Saveetha Medical College, (SIMATS), Chennai, India
4 Department of Biochemistry, Nimra Institute of Medical Sciences,Vijayawada, India
10.2478/cipms-2023-0009
© 2023 Author(s). This is an open access article distributed under the Creative Commons Attribution-NonComercial-No Derivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/)
Abstract
Introduction. Type 2 diabetes mellitus is the root cause of diabetic nephropathy, a condition affecting the kidneys (T2DM). The number of people who have type 2 diabetes is growing.
Aim. To evaluate the differences in Apelin 13 levels between patients with T2DM who had normal or microalbuminuria and those who had microalbuminuria, as well as between these patients and healthy controls. The intent is to better understand its link to microalbumin, haemoglobin A1c, insulin resistance (IR), and other standard measures.
Materials and methods. Sixty individuals with type 2 diabetes, aged 35 to 45, were selected, and their microalbuminuria and normoalbuminuria were compared. Thirty age-matched healthy volunteers were selected to serve as controls. The concentrations of Apelin 13 and insulin in the plasma were measured with ELISA kits. The Turbilatex assay was used to calculate microalbumin concentrations. Measurements of glycosylated haemoglobin (HbA1C) were made via high-performance liquid chromatography.
Results. Patients with type 2 diabetes mellitus had higher levels of the protein Apelin 13 in their plasma than did healthy controls. T2DM patients with microalbuminuria were different from normoalbuminuric patients in another important way. Correlations between plasma Apelin 13 and albuminuria, HbA1c, and HOMA-IR were all positive.
Conclusion. Considering that plasma Apelin 13 is a critical risk factor in Type 2 diabetes mellitus and frequently arises in the early stages of nephropathy, it may be useful for the assessment of vascular issues in type 2 diabetic patients.
Full Text
Keywords
Apelin 13, type 2 diabetes (T2 DM), microalbumin, glycosylated hemoglobin (HbA1C).
References
- International Diabetes Federation. IDF diabetes atlas. 7. Brussels: International Diabetes Federation; 2015.
- Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64-S71.
- Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840-6
- Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162-72.
- Huang Z, Luo X, Liu M, Chen L. Function and regulation of apelin. APJ system in digestive physiology and pathology. J Cell Physiol. 2019;234:7796-810.
- Roche J, Rame C, Reverchon M, Mellouk N, Cornuau M, Guerif F, et al. Apelin (APLN) and Apelin Receptor (APLNR) in human ovary: expression, signaling, and regulation of steroidogenesis in primary human luteinized granulosa cells. Biol Reprod. 2016;95:104.
- Liu W, Yan J, Pan W, Tang M. Apelin/Elabela-APJ: anovel therapeutic target in the cardiovascular system. Ann Transl Med. 2020;8(5):243.
- Wan T, Fu M, Jiang Y, Jiang W, Li P, Zhou S. Research progress on mechanism of neuroprotective roles of Apelin-13 in Prevention and Treatment of Alzheimer’s Disease. Neurochem Res. 2021;47(2):205-17.
- Zhou JX, Shuai NN, Wang B, Jin X, Kuang X, Tian SW. Neuroprotective gain of Apelin/APJ system. Neuropeptides. 2021;87: 102131.
- Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A, et al. Plasma Apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes. 2007;115(7):428-32.
- Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, et al. LDL-cholesterol lowering increases plasma Apelin in isolated hypercholesterolemia. Atherosclerosis. 2009;204(1):222-8.
- Patlak M. New weapons to combat an ancient disease: treating diabetes. FASEB J. 2002;16(14):1853.
- Maitra A, Abbas AK. Endocrine system. In: Kumar V, Fausto N, Abbas AK (eds). Robbins and Cotran Pathologic basis of disease (7th ed).Philadelphia: Saunders; 2005:1156-226.
- Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nat Rev Endocrinol. 2011;8(4):228-36.
- Genetic basis of type 1 and type 2 diabetes, obesity, and their complications. Advances and emerging opportunities in diabetes research: a Strategic Planning report of the DMICC. [www.niddk.nih.gov/NR] (access 22 December 2011).
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, TreacherFF, Turner RC.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.
- Kartal H, Comu FM, Kucuk A, Polat Y, Dursun AD, Arslan M. Effect of Apelin-13 on erythrocyte deformability during ischaemia-reperfusion injury of heart in diabetic rats. Bratisl Lek Listy. 2017;118(3):133-6
- Du JH, Li X, Li R, Xu L, Ma RR, Liu SF, et al. Elevation of serum Apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients. Int J Ophthalmol. 2014;7(6):968-73.
- Chen H, Li J, Jiao L, Petersen RB, Li J, Peng A, et al. Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse. J Physiol. 2014;592(3):505-21.
- Castan-Laurell I, Masri B, Valet P. The apelin/APJ system as a therapeutic target in metabolic diseases. Expert Opin Ther Targets. 2019;23:215-25
- Sawane M, Kajiya K, Kidoya H, Takagi M, Muramatsu F, Takakura N. Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. Diabetes. 2013;62:1970-80
- Hu H, He L, Li L, Chen L. Apelin/APJ system as a therapeutic target in diabetes and its complications. Mol Genet Metab. 2016;119:20-7
- Palmer ES, Nigel I, O’Harte FPM.Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: An Update. Clin Med Insights Endocrinol Diabetes. 2022;15:11795514221074679.
- Duparc T, Colom A, Cani PD, Massaly N, Rastrelli S, Drougard A, et al. Central apelin controls glucose homeostasisviaa nitric oxide-dependent pathway in mice. Antioxid Redox Signal. 2011;15:1477-96.
- Han S, Englander EW, Gomez GA, Rastellini C, Quertermous T, Kundu RK, et al. Pancreatic islet APJ deletion reduces islet density and glucose tolerance in mice. Endocrinology. 2015;156:2451-60.
- Zhang BH, Wang W, Wang H, YinJ, Zeng XJ. Promoting effects of the adipokine, apelin, on diabetic nephropathy. PLoS One. 2013;8(4):e60457.
- Dawood A, Abdelraof M, El Ghobashy Y. The relationship between serum apelin level and different grades of diabetic nephropathy in type 2 diabetic patients. Egypt J Obes Diabetes Endocrinol. 2017;3(1):32.
- Day RT, Cavaglieri RC, Feliers D. Apelin retards the progression of diabetic nephropathy. Am J Physiol Renal Physiol. 2013;304: F788-F800.
